Expert Interview
A look at Roche’s Results from the Phase III evERA Trial of oral Giredestrant plus everolimus in Post-CDK4/6 treated Breast Cancer Patients
Ticker(s): RHHBYInstitution: StonyBrook Cancer Center
- Chief, Division of Hematology/Oncology and Associate Director of Clinical and Translational Research at Stony Brook Cancer Center.
- Manages approximately 10 patients with HR+/HER2- mBC.
- Clinical research in breast cancer include biomarker discovery including the use of functional imaging for predicting breast cancer risk and response to antitumor therapies and role of non-steroidal anti-inflammatory drugs (NSAIDs) in breast cancer prevention.
Given the evERA results, how do you see the role of oral SERDs like giredestrant evolving in the treatment landscape for ER+/HER2- metastatic breast cancer, particularly after CDK4/6 inhibitor progression?
Added By: sara_adminHow do giredestrant + everolimus outcomes compare with existing standard endocrine therapy + everolimus in terms of efficacy and tolerability, and is the differentiation clinically significant?
Added By: sara_adminDo you anticipate a niche role for giredestrant in combination settings, or could oral SERDs eventually displace aromatase inhibitors and fulvestrant in broader lines of therapy?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
